These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23532530)

  • 21. The safety and efficacy of lorcaserin in the management of obesity.
    Hess R; Cross LB
    Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lorcaserin for weight loss: insights into US Food and Drug Administration approval.
    Miller LE
    J Acad Nutr Diet; 2013 Jan; 113(1):25-30. PubMed ID: 23260720
    [No Abstract]   [Full Text] [Related]  

  • 23. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.
    Nguyen CT; Zhou S; Shanahan W; Fain R
    Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity.
    Tchang BG; Abel B; Zecca C; Saunders KH; Shukla AP
    Expert Opin Pharmacother; 2020 Jan; 21(1):21-28. PubMed ID: 31693425
    [No Abstract]   [Full Text] [Related]  

  • 25. Lorcaserin Hcl for the treatment of obesity.
    Shukla AP; Kumar RB; Aronne LJ
    Expert Opin Pharmacother; 2015; 16(16):2531-8. PubMed ID: 26472579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and tolerability review of lorcaserin in clinical trials.
    Greenway FL; Shanahan W; Fain R; Ma T; Rubino D
    Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of lorcaserin on pre-existing valvulopathy: A pooled analysis of phase 3 trials.
    Weissman NJ; Smith SR; Fain R; Hall N; Shanahan WR
    Obesity (Silver Spring); 2017 Jan; 25(1):39-44. PubMed ID: 27888609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lorcaserin--not a new weapon in the battle with appetite.
    Halford JC
    Nat Rev Endocrinol; 2010 Dec; 6(12):663-4. PubMed ID: 21102648
    [No Abstract]   [Full Text] [Related]  

  • 29. Trial of lorcaserin for weight management.
    von Haehling S
    N Engl J Med; 2010 Dec; 363(25):2468; author reply 2469-70. PubMed ID: 21158671
    [No Abstract]   [Full Text] [Related]  

  • 30. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
    Bohula EA; Scirica BM; Fanola C; Inzucchi SE; Keech A; McGuire DK; Smith SR; Abrahamsen T; Francis BH; Miao W; Perdomo CA; Satlin A; Wiviott SD; Sabatine MS
    Am Heart J; 2018 Aug; 202():39-48. PubMed ID: 29803985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of impulsivity and reward in the anti-obesity actions of 5-HT
    Higgins GA; Zeeb FD; Fletcher PJ
    J Psychopharmacol; 2017 Nov; 31(11):1403-1418. PubMed ID: 29072522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration.
    Grabarczyk TR
    Pharmacotherapy; 2018 Jan; 38(1):19-28. PubMed ID: 29044720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential.
    Higgins GA; Fletcher PJ; Shanahan WR
    Pharmacol Ther; 2020 Jan; 205():107417. PubMed ID: 31629010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles.
    Higgins GA; Silenieks LB; Lau W; de Lannoy IA; Lee DK; Izhakova J; Coen K; Le AD; Fletcher PJ
    Psychopharmacology (Berl); 2013 Apr; 226(3):475-90. PubMed ID: 23184281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of lorcaserin for the treatment of obesity.
    Berlie HD; Hurren KM
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1053-9. PubMed ID: 23802690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trial of lorcaserin for weight management.
    Jia J; Xiong L; Chen S
    N Engl J Med; 2010 Dec; 363(25):2468-9; author reply 2469-70. PubMed ID: 21158670
    [No Abstract]   [Full Text] [Related]  

  • 37. Lorcaserin approval in the United States: paving the way?
    Pedersen SD; Astrup A
    Endocrinol Nutr; 2012 Nov; 59(9):521-2. PubMed ID: 22939712
    [No Abstract]   [Full Text] [Related]  

  • 38. Lorcaserin for the treatment of obesity.
    Redman LM; Ravussin E
    Drugs Today (Barc); 2010 Dec; 46(12):901-10. PubMed ID: 21589947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study.
    Pirtle JL; Hickman MD; Boinpelly VC; Surineni K; Thakur HK; Grasing KW
    Pharmacol Biochem Behav; 2019 May; 180():52-59. PubMed ID: 30811963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lorcaserin. In obesity: unacceptable risks.
    Prescrire Int; 2014 May; 23(149):117-20. PubMed ID: 24926508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.